Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. - Wikidata - wikimedia - TriplyDB

Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.

Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.

http://www.wikidata.org/entity/Q35827892

about

KSHV-Mediated Angiogenesis in Tumor Progression Recapitulation of acquired immuno deficiency syndrome associated Kaposi's sarcoma Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients HIV-associated chronic immune activation.Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi's sarcoma.Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)--an update.Review of latent and lytic phase biomarkers in Kaposi's sarcoma.Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.Diagnosis and Treatment of Kaposi Sarcoma.Infection of KSHV and Interaction with HIV: The Bad Romance.Kaposi's Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology.Endothelial cell malignancies: new insights from the laboratory and clinic.Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infections

P2860

Q26742030-12D731AA-45DA-466B-A880-3A28DB33DB70 Q28080182-C3BCA78F-5534-4572-BC7C-A2126B730F17 Q33575261-83708C50-C9C5-4588-9234-48D006C5072D Q34653277-CE91D580-0AFC-4E55-8230-F5568D4A3CF9 Q34663095-63A797A7-502A-4AB6-8135-829513ECA582 Q35895560-B69A6949-514A-4FDF-A3CB-22DF277C0A1B Q36318661-7CCF4CE1-57EC-4419-A3CD-C9BC8D7C15E2 Q36557592-D7A1A5E9-416F-4166-A294-61554276AEF1 Q36745445-C3ECADE9-9262-481A-AC4D-E49892922B74 Q38081246-3197C1B1-D30C-4A4A-84FD-BBA051CB2C02 Q38114627-30ACB32D-A87C-4F8D-A9F1-786FF879798F Q38144129-89569A2A-2FE5-4308-8E0F-7C59FA6DC1BC Q38943741-9D378184-CEDF-4233-BAB8-CA24C1BEE07A Q39190555-DBCA5762-5D95-4DD1-BA8F-6A17818E1B37 Q47606258-9120991B-CFBD-45D9-8624-64EEB80E4AEB Q47606321-506E3B48-11AD-4532-9A2E-44733D6FE3A7 Q55332047-13CEC265-1B27-4B00-AE94-F8C765B27464 Q56345322-00B95620-163D-463F-A9EA-F1D7DB9C870C

P2860

Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.

http://www.wikidata.org/entity/Q35827892

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@ast

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@en

type

label

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@ast

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@en

prefLabel

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@ast

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@en

P1433

Q35827892-08564966-6E91-415D-9E69-8DC153066C5D

P1476

Q35827892-9D27F004-4EEF-46B4-A960-E37BD4112D68

P2093

Q35827892-22BBEE04-7D32-4A2F-BEFB-88CCA2AB42D3

Q35827892-8BABA284-3555-4076-9077-67166E64AB6A

Q35827892-8DFE849B-3A98-4609-9C9A-5BE8A476A710

Q35827892-9E450500-2400-4B59-AB16-5E9D7BADC520

Q35827892-A25C2E68-9B03-46E6-8E8D-84730D6B100B

Q35827892-A63CF533-B759-47CC-8EA4-ACA202F25DBB

Q35827892-BACFAF81-997B-4D09-A21E-04406CCA8ED8

Q35827892-CC96817A-59EF-48D0-90F4-F18F7B7A853F

Q35827892-ED5AA1B5-6C77-4CE6-AF5D-53AEE69501BA

P2860

Q35827892-03EB0ABC-1AC6-446C-B8AB-B3A6FF54CD60

Q35827892-04B7674F-2BD6-4EA1-AE8B-ED0246A68F6B

Q35827892-04F74318-5FB7-4B97-9B86-2BE5699A29B9

Q35827892-1EFC0869-2739-41EB-A909-173FBAEEC609

Q35827892-24BC3F27-4616-4634-852F-CFC68C87C7B2

Q35827892-2F060295-3EE4-44E5-BF55-FD455240D2AF

Q35827892-3526CEBC-B949-46C2-B757-720EF75068B0

Q35827892-3801582F-3F3F-4511-A639-4B3E4548EA81

Q35827892-3AF9ACBF-2BFA-4370-8EE7-CA059532B5C5

Q35827892-3EF911F2-2F78-415F-AEBE-43848141CD26

P304

Q35827892-4A163928-C0E4-4BFF-B286-14A340A24A77

P31

Q35827892-4105BBFB-5BB5-4B4E-9955-816D354692FF

P356

Q35827892-AAB2DD43-6540-4EC8-9C15-36BB0F412727

P407

Q35827892-48B8CE5E-9EA0-4298-9C71-301EE0EA7AE2

P433

Q35827892-A40857EC-B201-49E2-B2AE-6AAF82AC361C

P478

Q35827892-DF521FE6-66A3-4928-A569-4192D60917CB

P577

Q35827892-49A77A27-2A19-4AD1-8A89-8A4858AF02FD

P5875

Q35827892-01F59108-6EA4-490F-90EC-9177D71C9246

P698

Q35827892-E37745F4-A21C-4972-A415-D0C39E51F9BF

P921

Q35827892-3E3533B8-EFAA-4616-94F4-53BA49D79E6C

Q35827892-86606D9E-3800-4DEE-9845-1153204A52CD

P932

Q35827892-B3A12DBD-0620-4D81-BB74-8238D031AEA8

P356

QAI.0B013E31823E7884

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Rapamycin with antiretroviral ...... S Malignancy Consortium study.

@en

P2093

Bruce J Dezube

http://www.w3.org/2001/XMLSchema#string

Debasmita Roy

http://www.w3.org/2001/XMLSchema#string

Dirk P Dittmer

http://www.w3.org/2001/XMLSchema#string

Erin G Reid

http://www.w3.org/2001/XMLSchema#string

Ethel Cesarman

http://www.w3.org/2001/XMLSchema#string

Jeannette Y Lee

http://www.w3.org/2001/XMLSchema#string

Kelong Han

http://www.w3.org/2001/XMLSchema#string

Raman Venkataramanan

http://www.w3.org/2001/XMLSchema#string

Susan E Krown

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

Kaposi's sarcoma in sub-Saharan Africa: a current perspective.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Spectrum of cancer risk late after AIDS onset in the United States.

The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication

Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

P304

447-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E31823E7884

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51783629

http://www.w3.org/2001/XMLSchema#string

P698

22067664

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3302934

http://www.w3.org/2001/XMLSchema#string